Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

PURPOSE: Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit from approved anticancer drugs outside their label si...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoes, Louisa R., van Berge Henegouwen, Jade M., van der Wijngaart, Hanneke, Zeverijn, Laurien J., van der Velden, Daphne L., van de Haar, Joris, Roepman, Paul, de Leng, Wendy J., Jansen, Anne M.L., van Werkhoven, Erik, van der Noort, Vincent, Huitema, Alwin D.R., Gort, Eelke H., de Groot, Jan Willem B., Kerver, Emile D., de Groot, Derk Jan, Erdkamp, Frans, Beerepoot, Laurens V., Hendriks, Mathijs P., Smit, Egbert F., van der Graaf, Winette T.A., van Herpen, Carla M.L., Labots, Mariette, Hoeben, Ann, Morreau, Hans, Lolkema, Martijn P., Cuppen, Edwin, Gelderblom, Hans, Verheul, Henk M.W., Voest, Emile E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365364/
https://www.ncbi.nlm.nih.gov/pubmed/35046062
http://dx.doi.org/10.1158/1078-0432.CCR-21-3752

Ejemplares similares

Ejemplares similares